ArticleFuture oncology (London, England)2026

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Stephen J Freedland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.